We ensure the creation of unique models and comprehensive services
- Cell & Gene Therapy
- Small Molecules
- Cell line-derived xenograft models
- Syngeneic models
- Humanized mouse models
- Patient-derived xenograft models
- Graft vs Host disease (GvHD) models
We ensure creation of unique models and comprehensive services
- Expansion & activation of CAR-T cells
- Flexibility to build out T-cell production capabilities
- Flow cytometry-based assays to support immuno-oncology drug development
- IVIS live animal imaging
- Cytotoxicity & Immunotoxicity assays
- PK/PD & efficacy studies
- Flow and PCR based biodistribution assays
In Vivo Cancer Models
Noble Scientists have deep experience designing and implementing a variety of animal models to characterize oncology drug candidates for efficacy, pharmacodynamics, pharmacokinetics, toxicity and bioavailability. Models include:
- Humanized rodent models for immune-oncological studies
- Syngeneic tumor models for immuno-oncological drug studies
- Oncolytic virus mediated cancer therapy model
Patient Derived Xenograft (PDX)
- Ectopic & Orthotopic
Cell Line Derived Xenograft (CDX)
- Immunocompromised rodent models for CAR – T treatment studies
- Xenograft Models
- Breast Adenocarcinoma Model
- Orthotopic & Ectopic Models
- Breast tumor in mammary fat pad
- Liver tumor
- Glioma or other kinds of Brain tumors
- Metastatic Models
- Leukemia Models
- Cell Therapy Models
The Industry Standard
Noble’s OncoDiversity Cell Line Panel will hit the target
Noble will screen your drug candidates using our OncoDiversity Cell Line Panel, a diverse collection of cell lines spanning multiple cancer indications.
Results from the cell line panel screen can be matched to the genetic background in the cancer cell lines to determine a molecular biomarker profile correlating with the activity of your drug candidate.
Noble’s biobank resource containing DNA and protein from each cell line is then used to confirm the drug: biomarker correlations that were discovered in the cell panel screen.
Validation of the drug and biomarker response in vivo can be carried out in cell models shown to be sensitive to your drug.
These studies provide an understanding of the expression status of the target and molecular pathway in the selected model; determination of the active plasma concentrations of the drug; modulation of the downstream pathway in which the target functions; and assessment of the therapeutic index.
By examining the response of a broad spectrum of validated DNA and protein-based biomarkers to therapeutics, we deliver data that enables more confident decisions.
Scientific Advisor Team
Our oncology team is committed to fight The Fight
by advancing your preclinical research.
Stephen K. Horrigan, Ph.D.
Chief Scientific Officer
Pang-Kuo Lo, Ph.D. MSc
Team Lead, Assay Development
Arundhati Ghosh, Ph.D., MSc
Yongping Chen, M.D., Ph.D.
Senior Study Director
We can help to lead the global fight against cancer
Resources & White Papers
PASSIONATE ABOUT COLLABORATING FOR A CURE
Orthotopic Liver Cancer Model Established in Athymic Nude Mice
Introduction The study aims to establish an orthotopic liver cancer model in nude mice and evaluate the anti-tumor efficacy of Sorafenib. Liver cancer is a leading cause of...
Mouse Peritonitis/Sepsis Model of MRSA Infection
Noble Life Sciences, in collaboration with ImQuest Biosciences, has optimized the peritonitis/sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). The model’s popularity derives from its ease of use with small and expensive animals, short-duration experiments with reproducible infections, and simple end-points.
Animal Models for the development of vaccines and therapeutics for influenza infections
The mouse and ferret animal models are the most widely used models for influenza studies. Each has...
Immunophenotyping of Tumor-Infiltrating Immune Cells in Mouse Syngeneic Tumor Models Using Multi-Color Flow Cytometry Assays
The in vivo animal tumor models possessing fully functional immunity are essential for preclinical research of new immunotherapeutic medicine. Syngeneic tumor models are...